None listed
Conditions
Interventions
Intervention1: A supplement: to be taken three times daily for 21days
Intervention2: A supplement: 500mg capsule to be taken once a day.
Total duration of therapy is 21days
Control Intervention1: Plac
Sponsors
Aurea Biolabs P Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Subject has provided written and dated informed consent to participate in the study. Subject is willing and able to comply with the protocol. Subject is a male between 19 and 29 years of age, inclusive. Subject is in good health as determined by a health history questionnaire. Subject is untrained in resistance/power exercise
Exclusion criteria
Exclusion criteria: Subject is participating in another clinical trial or has received an investigational product within thirty days prior to enrollment. Subject has a history of alcohol or other drug abuse in the past year. Subject has a significant history or current presence of treated or untreated bleeding disorder, diabetes mellitus, high blood pressure (BP) [systolic BP > 140 and/or diastolic BP > 90], thyroid disease, tachyarrhythmia, heart disease, kidney disease, or liver disease. Subject currently suffers from a sleep disorder and/or has a known history of (or is currently being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s), which in the opinion of the investigator, might put the subject at risk and/or confound the results of the study. Subject has a known allergy or sensitivity to any ingredient in the test product. Subject has any medical condition or uses any medication, nutritional product, dietary supplement or program, which in the opinion of the investigator, might interfere with the conduct of the study or place the subject at risk. Subject has a history of difficulty swallowing large pills or tablets. Subject has used creatine within 9 weeks prior to screening. Subject has a history of orthopedic injury or surgery within the last year. Subject has any physical condition considered a contra-indication to the type of exercise performed in the study. Subject has had an abnormal resting ECG. Investigator is uncertain about subjectâ??s capability or willingness to comply with the protocol requirements.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Adverse event reportsTimepoint: day1 day21 | — |
Primary
| Measure | Time frame |
|---|---|
| Change in isometric strength Change in flexibility Change in blood parametersTimepoint: day1 day21 | — |
Countries
India
Contacts
Public ContactDivya C
BioAgile Therapeutics Pvt Ltd
Outcome results
None listed